Identification

Name
Bupranolol
Accession Number
DB08808
Type
Small Molecule
Groups
Approved
Description

Bupranolol is a non-selective beta blocker without intrinsic sympathomimetic activity (ISA), but with strong membrane stabilizing activity. Its potency is similar to "propranolol":http://www.drugbank.ca/drugs/DB00571.

Structure
Thumb
Synonyms
  • Bupranol
Product Ingredients
IngredientUNIICASInChI Key
Bupranolol hydrochlorideDTC2G3GDPL15148-80-8WJUUZHQWGKSLIJ-UHFFFAOYSA-N
International/Other Brands
Betadrenol (Desma) / Ophtorenin (Winzer (Germany))
Categories
UNII
858YGI5PIT
CAS number
14556-46-8
Weight
Average: 271.783
Monoisotopic: 271.13390666
Chemical Formula
C14H22ClNO2
InChI Key
HQIRNZOQPUAHHV-UHFFFAOYSA-N
InChI
InChI=1S/C14H22ClNO2/c1-10-5-6-12(15)13(7-10)18-9-11(17)8-16-14(2,3)4/h5-7,11,16-17H,8-9H2,1-4H3
IUPAC Name
1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol
SMILES
CC1=CC(OCC(O)CNC(C)(C)C)=C(Cl)C=C1

Pharmacology

Indication

Used to manage hypertension and tachycardia. Also used to treat glaucoma.

Pharmacodynamics

Bupranolol is a competitive, nonselective beta-blocker similar to propanolol without intrinsic sympathomimetic activity.

Mechanism of action

Bupranolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension.

TargetActionsOrganism
ABeta-1 adrenergic receptor
antagonist
Human
UBeta-2 adrenergic receptor
antagonist
Human
UBeta-3 adrenergic receptor
antagonist
Human
Absorption

Quickly and completely absorbed from the gut with less than 10% oral bioavailability.

Volume of distribution
Not Available
Protein binding

76%

Metabolism

Over 90% undergo first-pass metabolism. The main metabolite is carboxybupranolol, 4-chloro-3-[3-(1,1-dimethylethylamino)-2-hydroxy-propyloxy]benzoic acid, of which 88% are eliminated renally within 24 hours.

Route of elimination
Not Available
Half life

2-4 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include bradycardia, cardiac failure, hypotension, and brochospasm.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Bupranolol Action PathwayDrug action
Bupranolol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may decrease the antihypertensive activities of Bupranolol.Investigational
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Bupranolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Bupranolol.Experimental
AbediterolBupranolol may decrease the bronchodilatory activities of Abediterol.Investigational
AcebutololAcebutolol may increase the hypotensive activities of Bupranolol.Approved, Investigational
AceclofenacAceclofenac may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
AcemetacinThe therapeutic efficacy of Bupranolol can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineBupranolol may increase the orthostatic hypotensive activities of Acepromazine.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Bupranolol.Approved
AcetohexamideBupranolol may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Acetylcholine.Approved
AcetyldigitoxinBupranolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinBupranolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Bupranolol.Approved
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Bupranolol.Experimental, Investigational
AlaproclateThe serum concentration of Bupranolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Bupranolol.Approved, Withdrawn
AlfentanilAlfentanil may increase the bradycardic activities of Bupranolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Bupranolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
AliskirenBupranolol may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Bupranolol.Experimental
AlprenololAlprenolol may increase the hypotensive activities of Bupranolol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Bupranolol.Approved
AmbrisentanBupranolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateBupranolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental, Investigational
AmifostineBupranolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AminophyllineBupranolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneThe therapeutic efficacy of Bupranolol can be increased when used in combination with Amiodarone.Approved, Investigational
AmitrazAmitraz may increase the atrioventricular blocking (AV block) activities of Bupranolol.Vet Approved
AmitriptylineBupranolol may increase the orthostatic hypotensive activities of Amitriptyline.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Bupranolol.Approved
AmobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Bupranolol can be decreased when combined with Amodiaquine.Approved, Investigational
AmoxapineBupranolol may increase the orthostatic hypotensive activities of Amoxapine.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Bupranolol.Approved, Illicit, Investigational
AndrographolideAndrographolide may decrease the antihypertensive activities of Bupranolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Bupranolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
ApocyninApocynin may decrease the antihypertensive activities of Bupranolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
ApremilastApremilast may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
ArbutamineBupranolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Arecoline.Experimental
ArformoterolBupranolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
AripiprazoleBupranolol may increase the orthostatic hypotensive activities of Aripiprazole.Approved, Investigational
AsenapineBupranolol may increase the orthostatic hypotensive activities of Asenapine.Approved
AtenololAtenolol may increase the hypotensive activities of Bupranolol.Approved
AvanafilAvanafil may increase the antihypertensive activities of Bupranolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Bupranolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Bupranolol.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
BambuterolBupranolol may decrease the bronchodilatory activities of Bambuterol.Approved, Investigational
BarbexacloneThe serum concentration of Bupranolol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Barbital.Illicit
BarnidipineBupranolol may increase the antihypertensive activities of Barnidipine.Approved
BendazacBendazac may decrease the antihypertensive activities of Bupranolol.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Bupranolol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Bupranolol.Withdrawn
BenorilateBenorilate may decrease the antihypertensive activities of Bupranolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Bupranolol.Withdrawn
BenzphetamineThe therapeutic efficacy of Benzphetamine can be decreased when used in combination with Bupranolol.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Bupranolol.Approved
BepridilBepridil may increase the hypotensive activities of Bupranolol.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Bupranolol.Approved, Investigational
BethanecholThe risk or severity of adverse effects can be increased when Bupranolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BevantololBupranolol may increase the orthostatic hypotensive activities of Bevantolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Bupranolol.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Bupranolol.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Bupranolol.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Bupranolol.Approved
BitolterolBupranolol may decrease the bronchodilatory activities of Bitolterol.Withdrawn
BL-1020BL-1020 may increase the hypotensive activities of Bupranolol.Investigational
BosentanBosentan may increase the hypotensive activities of Bupranolol.Approved, Investigational
BQ-123Bupranolol may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the hypotensive activities of Bupranolol.Approved
BrexpiprazoleBupranolol may increase the orthostatic hypotensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the antihypertensive activities of Bupranolol.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Bupranolol.Experimental
BromfenacBromfenac may decrease the antihypertensive activities of Bupranolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Bupranolol.Investigational
BucindololBupranolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Bupranolol.Approved, Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Bupranolol.Experimental
BunazosinBupranolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Bupranolol.Approved, Investigational
BupropionThe metabolism of Bupranolol can be decreased when combined with Bupropion.Approved
CabergolineBupranolol may increase the vasoconstricting activities of Cabergoline.Approved
CadralazineCadralazine may increase the hypotensive activities of Bupranolol.Experimental
CafedrineBupranolol may increase the hypotensive activities of Cafedrine.Investigational
CaffeineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Caffeine.Approved
CandesartanBupranolol may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Bupranolol.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Bupranolol.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Bupranolol.Approved
CarbamoylcholineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Bupranolol.Experimental, Investigational
CarbutamideBupranolol may increase the hypoglycemic activities of Carbutamide.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Bupranolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Bupranolol.Approved
CarvedilolBupranolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Bupranolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
CeliprololBupranolol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Bupranolol can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Bupranolol.Experimental
ChlorpromazineBupranolol may increase the orthostatic hypotensive activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideBupranolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Bupranolol.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Bupranolol.Approved
CicletanineBupranolol may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Bupranolol.Approved
CimetidineThe metabolism of Bupranolol can be decreased when combined with Cimetidine.Approved, Investigational
ClemastineThe metabolism of Bupranolol can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolBupranolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Bupranolol.Approved
CloranololBupranolol may increase the hypotensive activities of Cloranolol.Experimental
ClozapineBupranolol may increase the orthostatic hypotensive activities of Clozapine.Approved
CoumaphosCoumaphos may increase the bradycardic activities of Bupranolol.Vet Approved
CryptenamineCryptenamine may increase the hypotensive activities of Bupranolol.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
CyclopenthiazideBupranolol may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe risk or severity of hyperkalemia can be increased when Bupranolol is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinBupranolol may increase the bradycardic activities of Cymarin.Experimental
DapiprazoleBupranolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved
DapoxetineThe serum concentration of Bupranolol can be increased when it is combined with Dapoxetine.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Bupranolol.Approved, Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Bupranolol.Approved
DelaprilBupranolol may increase the hypotensive activities of Delapril.Investigational
DemecariumDemecarium may increase the bradycardic activities of Bupranolol.Approved
DeserpidineBupranolol may increase the hypotensive activities of Deserpidine.Approved
DeslanosideBupranolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Bupranolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
DetomidineDetomidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Vet Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Vet Approved
DexniguldipineDexniguldipine may increase the hypotensive activities of Bupranolol.Experimental
DextroamphetamineBupranolol may increase the orthostatic hypotensive activities of Dextroamphetamine.Approved, Illicit
DiazoxideDiazoxide may increase the hypotensive activities of Bupranolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Bupranolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of Bupranolol.Investigational
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Bupranolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
DigitoxinBupranolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinBupranolol may increase the bradycardic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Bupranolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydralazineDihydralazine may increase the hypotensive activities of Bupranolol.Approved, Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Bupranolol.Approved, Investigational
DiphenhydramineThe metabolism of Bupranolol can be decreased when combined with Diphenhydramine.Approved, Investigational
DipivefrinBupranolol may decrease the bronchodilatory activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Bupranolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Bupranolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Bupranolol.Experimental
DL-MethylephedrineDL-Methylephedrine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
DobutamineBupranolol may decrease the bronchodilatory activities of Dobutamine.Approved
DonepezilDonepezil may increase the bradycardic activities of Bupranolol.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Bupranolol.Approved
DoxazosinBupranolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxepinBupranolol may increase the orthostatic hypotensive activities of Doxepin.Approved, Investigational
DoxofyllineBupranolol may decrease the bronchodilatory activities of Doxofylline.Approved, Investigational
DronedaroneDronedarone may increase the bradycardic activities of Bupranolol.Approved
DroperidolBupranolol may increase the orthostatic hypotensive activities of Droperidol.Approved, Vet Approved
DroxicamDroxicam may decrease the antihypertensive activities of Bupranolol.Withdrawn
DroxidopaBupranolol may decrease the bronchodilatory activities of Droxidopa.Approved, Investigational
DuloxetineThe serum concentration of Bupranolol can be increased when it is combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Bupranolol.Investigational
DyphyllineBupranolol may decrease the bronchodilatory activities of Dyphylline.Approved
E-6201E-6201 may decrease the antihypertensive activities of Bupranolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Bupranolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Bupranolol.Approved
EfonidipineEfonidipine may increase the hypotensive activities of Bupranolol.Approved, Investigational
EnalaprilatBupranolol may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Bupranolol.Experimental
EpanololBupranolol may increase the hypotensive activities of Epanolol.Experimental
EphedraBupranolol may decrease the bronchodilatory activities of Ephedra.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Epibatidine.Experimental
EpinephrineBupranolol may decrease the bronchodilatory activities of Epinephrine.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Bupranolol.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Bupranolol.Approved
EprosartanEprosartan may increase the hypotensive activities of Bupranolol.Approved
Ergoloid mesylateBupranolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineBupranolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
EscitalopramBupranolol may increase the orthostatic hypotensive activities of Escitalopram.Approved, Investigational
EtafedrineBupranolol may decrease the bronchodilatory activities of Etafedrine.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Bupranolol.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Bupranolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
EtomidateThe therapeutic efficacy of Etomidate can be decreased when used in combination with Bupranolol.Approved
EtoperidoneThe serum concentration of Bupranolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Bupranolol.Investigational, Nutraceutical
ExisulindExisulind may decrease the antihypertensive activities of Bupranolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Bupranolol.Experimental
FelodipineFelodipine may increase the hypotensive activities of Bupranolol.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Bupranolol.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Bupranolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Bupranolol.Approved
FenoterolBupranolol may decrease the bronchodilatory activities of Fenoterol.Approved, Investigational
FentanylFentanyl may increase the bradycardic activities of Bupranolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Bupranolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Bupranolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Bupranolol.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Bupranolol.Experimental
FingolimodBupranolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Floctafenine.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Bupranolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Bupranolol.Experimental
FluoxetineThe serum concentration of Bupranolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolBupranolol may increase the orthostatic hypotensive activities of Flupentixol.Approved, Investigational, Withdrawn
FluphenazineFluphenazine may increase the hypotensive activities of Bupranolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
FluvoxamineThe metabolism of Bupranolol can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolBupranolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Bupranolol.Approved
FostamatinibFostamatinib may increase the antihypertensive activities of Bupranolol.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Bupranolol.Approved, Investigational, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Bupranolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Bupranolol.Approved
GanciclovirThe risk or severity of adverse effects can be increased when Bupranolol is combined with Ganciclovir.Approved, Investigational
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Bupranolol.Approved, Investigational, Nutraceutical
GitoformateBupranolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideBupranolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideBupranolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideBupranolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideBupranolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidoneBupranolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideBupranolol may increase the hypoglycemic activities of Glisoxepide.Investigational
GlyburideBupranolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Bupranolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Bupranolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Bupranolol.Approved
GuanazodineBupranolol may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Bupranolol.Approved
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Bupranolol.Approved, Investigational
GuanoclorBupranolol may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzBupranolol may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanBupranolol may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Bupranolol.Experimental
HexamethoniumBupranolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Hexobarbital.Approved
HexoprenalineBupranolol may decrease the bronchodilatory activities of Hexoprenaline.Approved, Withdrawn
HigenamineHigenamine may decrease the antihypertensive activities of Bupranolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Bupranolol.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Bupranolol.Experimental
HydralazineHydralazine may increase the hypotensive activities of Bupranolol.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Bupranolol.Approved, Investigational
HydroxychloroquineThe metabolism of Bupranolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Bupranolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Bupranolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
IloperidoneBupranolol may increase the orthostatic hypotensive activities of Iloperidone.Approved
IloprostIloprost may increase the hypotensive activities of Bupranolol.Approved, Investigational
ImidaprilBupranolol may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Bupranolol.Experimental
ImipramineBupranolol may increase the orthostatic hypotensive activities of Imipramine.Approved
IndacaterolBupranolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Bupranolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the hypotensive activities of Bupranolol.Approved
IndenololBupranolol may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenIndobufen may decrease the antihypertensive activities of Bupranolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Bupranolol.Withdrawn
IndoraminBupranolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin HumanBupranolol may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkBupranolol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Bupranolol.Experimental
IproclozideIproclozide may increase the hypotensive activities of Bupranolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Bupranolol.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Bupranolol.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Bupranolol.Approved
IsoetarineBupranolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Bupranolol.Approved, Investigational, Withdrawn
IsoprenalineBupranolol may decrease the bronchodilatory activities of Isoprenaline.Approved, Investigational
IsoxicamIsoxicam may decrease the antihypertensive activities of Bupranolol.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Bupranolol.Approved, Investigational
KebuzoneKebuzone may decrease the antihypertensive activities of Bupranolol.Experimental
KetanserinKetanserin may increase the hypotensive activities of Bupranolol.Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Bupranolol.Approved
LabetalolBupranolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineLacidipine may increase the hypotensive activities of Bupranolol.Approved, Investigational
Lanatoside CBupranolol may increase the bradycardic activities of Lanatoside C.Experimental
LatanoprostLatanoprost may increase the hypotensive activities of Bupranolol.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Bupranolol.Approved, Investigational
LevomilnacipranThe serum concentration of Bupranolol can be increased when it is combined with Levomilnacipran.Approved, Investigational
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
LevosalbutamolBupranolol may decrease the bronchodilatory activities of Levosalbutamol.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Bupranolol.Approved, Vet Approved
LinsidomineBupranolol may increase the hypotensive activities of Linsidomine.Experimental
LisdexamfetamineBupranolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilLisinopril may increase the hypotensive activities of Bupranolol.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Bupranolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Bupranolol.Experimental
LornoxicamLornoxicam may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Bupranolol.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
MacitentanBupranolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Bupranolol.Approved
MalathionMalathion may increase the bradycardic activities of Bupranolol.Approved, Investigational
ManidipineManidipine may increase the hypotensive activities of Bupranolol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Bupranolol.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Bupranolol.Approved, Investigational
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
MedetomidineMedetomidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Bupranolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Bupranolol.Approved, Investigational
MeloxicamMeloxicam may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Bupranolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Bupranolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Bupranolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Bupranolol.Approved, Investigational
MetahexamideBupranolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Bupranolol.Approved, Investigational, Withdrawn
MethacholineBupranolol may increase the bronchoconstrictory activities of Methacholine.Approved, Investigational
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Bupranolol.Investigational
MethohexitalThe serum concentration of Bupranolol can be decreased when it is combined with Methohexital.Approved
MethoserpidineBupranolol may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineBupranolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Approved, Investigational
MethyldopaMethyldopa may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Bupranolol.Approved, Investigational
MethylergometrineBupranolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
MethylphenobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Methylphenobarbital.Approved
MetildigoxinBupranolol may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololMetipranolol may increase the hypotensive activities of Bupranolol.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Bupranolol.Approved, Investigational
MetolazoneMetolazone may increase the hypotensive activities of Bupranolol.Approved
MetoprololMetoprolol may increase the hypotensive activities of Bupranolol.Approved, Investigational
MetyrosineBupranolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Bupranolol.Investigational, Withdrawn
MidodrineBupranolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Bupranolol can be increased when it is combined with Milnacipran.Approved, Investigational
MinaprineMinaprine may increase the bradycardic activities of Bupranolol.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Bupranolol.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Bupranolol.Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Bupranolol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Bupranolol.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Bupranolol.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Bupranolol.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Bupranolol.Approved, Investigational
MoricizineMoricizine may increase the hypotensive activities of Bupranolol.Approved, Investigational, Withdrawn
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
MuzolimineBupranolol may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Bupranolol.Approved
NabumetoneNabumetone may decrease the antihypertensive activities of Bupranolol.Approved
NadololNadolol may increase the hypotensive activities of Bupranolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Bupranolol.Approved
NaftopidilNaftopidil may increase the hypotensive activities of Bupranolol.Investigational
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Bupranolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
NebivololNebivolol may increase the hypotensive activities of Bupranolol.Approved, Investigational
NefazodoneBupranolol may increase the orthostatic hypotensive activities of Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Bupranolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Bupranolol.Withdrawn
NicardipineBupranolol may increase the orthostatic hypotensive activities of Nicardipine.Approved, Investigational
NicergolineBupranolol may increase the orthostatic hypotensive activities of Nicergoline.Approved, Investigational
NicorandilBupranolol may increase the hypotensive activities of Nicorandil.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Nicotine.Approved
NifedipineThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Bupranolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Bupranolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Bupranolol.Approved
NiguldipineBupranolol may increase the orthostatic hypotensive activities of Niguldipine.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Bupranolol.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Bupranolol.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Bupranolol.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Bupranolol.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Bupranolol.Approved, Investigational
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Bupranolol.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Bupranolol.Approved, Investigational
NorepinephrineBupranolol may decrease the bronchodilatory activities of Norepinephrine.Approved
NortriptylineBupranolol may increase the orthostatic hypotensive activities of Nortriptyline.Approved
NylidrinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Bupranolol.Approved
ObinutuzumabBupranolol may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Bupranolol.Withdrawn
OlanzapineBupranolol may increase the orthostatic hypotensive activities of Olanzapine.Approved, Investigational
OleandrinBupranolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Bupranolol.Approved, Investigational
OlodaterolBupranolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Bupranolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Bupranolol.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Bupranolol.Investigational
OrciprenalineBupranolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Bupranolol.Vet Approved
OuabainBupranolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Bupranolol.Approved
OxprenololOxprenolol may increase the hypotensive activities of Bupranolol.Approved
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bupranolol.Approved, Investigational
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Bupranolol.Approved, Withdrawn
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
PalmidrolPalmidrol may decrease the antihypertensive activities of Bupranolol.Experimental, Nutraceutical
ParaoxonParaoxon may increase the bradycardic activities of Bupranolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Bupranolol.Approved
PargylinePargyline may increase the hypotensive activities of Bupranolol.Approved
ParoxetineThe serum concentration of Bupranolol can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
Patent BlueThe therapeutic efficacy of Bupranolol can be decreased when used in combination with Patent Blue.Approved
PenbutololPenbutolol may increase the hypotensive activities of Bupranolol.Approved, Investigational
PentobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Bupranolol.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Bupranolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Bupranolol.Approved, Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilPerindopril may increase the hypotensive activities of Bupranolol.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Bupranolol.Approved
PeruvosideBupranolol may increase the bradycardic activities of Peruvoside.Experimental
PF-00610355Bupranolol may decrease the bronchodilatory activities of PF-00610355.Investigational
PhenelzinePhenelzine may increase the hypotensive activities of Bupranolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Bupranolol.Withdrawn
PhenobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineBupranolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Bupranolol.Withdrawn
PhentolamineBupranolol may increase the orthostatic hypotensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
PhenylephrineThe therapeutic efficacy of Phenylephrine can be decreased when used in combination with Bupranolol.Approved
PhenylpropanolamineBupranolol may decrease the bronchodilatory activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Bupranolol.Approved, Investigational
PilocarpineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Pilocarpine.Approved, Investigational
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Bupranolol.Approved
PindololPindolol may increase the hypotensive activities of Bupranolol.Approved, Investigational
PirbuterolBupranolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Bupranolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Bupranolol.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Bupranolol.Withdrawn
PizotifenBupranolol may increase the orthostatic hypotensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Bupranolol.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Bupranolol.Approved
Potassium ChlorideThe risk or severity of hyperkalemia can be increased when Potassium Chloride is combined with Bupranolol.Approved, Withdrawn
PranoprofenPranoprofen may decrease the antihypertensive activities of Bupranolol.Experimental, Investigational
PrazosinBupranolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Bupranolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Bupranolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcaineProcaine may increase the hypotensive activities of Bupranolol.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Bupranolol.Approved, Investigational
ProcaterolBupranolol may decrease the bronchodilatory activities of Procaterol.Approved, Investigational
ProchlorperazineThe serum concentration of Bupranolol can be increased when it is combined with Prochlorperazine.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Bupranolol.Experimental
PromazineBupranolol may increase the orthostatic hypotensive activities of Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Bupranolol can be increased when it is combined with Promethazine.Approved, Investigational
PropacetamolPropacetamol may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
PropafenoneThe risk or severity of adverse effects can be increased when Propafenone is combined with Bupranolol.Approved
PropericiazineBupranolol may increase the orthostatic hypotensive activities of Propericiazine.Approved, Investigational
PropiomazineBupranolol may increase the orthostatic hypotensive activities of Propiomazine.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Bupranolol.Vet Approved
PropiverineBupranolol may increase the orthostatic hypotensive activities of Propiverine.Approved, Investigational
PropranololPropranolol may increase the hypotensive activities of Bupranolol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Bupranolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Bupranolol.Experimental
ProscillaridinBupranolol may increase the bradycardic activities of Proscillaridin.Experimental
ProtokylolBupranolol may decrease the bronchodilatory activities of Protokylol.Approved, Vet Approved
PseudoephedrineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Bupranolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Bupranolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Bupranolol.Approved, Investigational
QuetiapineBupranolol may increase the orthostatic hypotensive activities of Quetiapine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Bupranolol.Approved, Investigational
QuinidineBupranolol may increase the orthostatic hypotensive activities of Quinidine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Bupranolol.Approved
RacepinephrineBupranolol may decrease the bronchodilatory activities of Racepinephrine.Approved
RamiprilRamipril may increase the hypotensive activities of Bupranolol.Approved
RasagilineRasagiline may increase the hypotensive activities of Bupranolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Bupranolol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Bupranolol.Approved
RemikirenRemikiren may increase the hypotensive activities of Bupranolol.Approved
RescinnamineBupranolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Bupranolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Bupranolol.Approved, Experimental, Investigational
RifapentineThe serum concentration of Bupranolol can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Bupranolol can be decreased when it is combined with Rifaximin.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Bupranolol.Approved, Investigational
RiociguatBupranolol may increase the hypotensive activities of Riociguat.Approved
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
RitodrineBupranolol may decrease the bronchodilatory activities of Ritodrine.Approved, Investigational
RituximabBupranolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineBupranolol may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Bupranolol.Approved, Investigational, Withdrawn
RomifidineRomifidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Vet Approved
RopiniroleThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Bupranolol.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Bupranolol.Withdrawn
SalbutamolBupranolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Bupranolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Bupranolol.Approved, Investigational, Vet Approved
SalmeterolBupranolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Bupranolol.Approved
SaprisartanSaprisartan may increase the hypotensive activities of Bupranolol.Experimental
SecobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Bupranolol.Approved, Investigational, Vet Approved
SelexipagBupranolol may increase the hypotensive activities of Selexipag.Approved
SemapimodSemapimod may decrease the antihypertensive activities of Bupranolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Bupranolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Bupranolol.Investigational
SertralineThe serum concentration of Bupranolol can be increased when it is combined with Sertraline.Approved
SildenafilSildenafil may increase the antihypertensive activities of Bupranolol.Approved, Investigational
SilodosinBupranolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SitaxentanBupranolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilSpirapril may increase the hypotensive activities of Bupranolol.Approved
SpironolactoneThe risk or severity of hyperkalemia can be increased when Spironolactone is combined with Bupranolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Bupranolol.Investigational
SufentanilSufentanil may increase the bradycardic activities of Bupranolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Bupranolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Bupranolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Bupranolol.Experimental
TacrineTacrine may increase the bradycardic activities of Bupranolol.Investigational, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Bupranolol.Approved, Investigational
TafenoquineThe metabolism of Bupranolol can be decreased when combined with Tafenoquine.Approved, Investigational
TalinololBupranolol may increase the hypotensive activities of Talinolol.Investigational
TamsulosinBupranolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Bupranolol.Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Bupranolol.Approved, Investigational
TemocaprilBupranolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the antihypertensive activities of Bupranolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Bupranolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Bupranolol.Vet Approved
TerazosinBupranolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbinafineThe metabolism of Bupranolol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineBupranolol may decrease the bronchodilatory activities of Terbutaline.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Bupranolol.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Bupranolol.Approved, Investigational
TetrahydropalmatineTetrahydropalmatine may increase the hypotensive activities of Bupranolol.Investigational
TheodrenalineBupranolol may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineBupranolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThe serum concentration of Bupranolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Bupranolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Bupranolol.Withdrawn
ThiopentalThe serum concentration of Bupranolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioproperazineBupranolol may increase the orthostatic hypotensive activities of Thioproperazine.Approved
ThioridazineBupranolol may increase the orthostatic hypotensive activities of Thioridazine.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Bupranolol.Approved
TiboloneBupranolol may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of Bupranolol.Withdrawn
TimololTimolol may increase the hypotensive activities of Bupranolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Bupranolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
TolazamideBupranolol may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineBupranolol may increase the orthostatic hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideBupranolol may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
TolmetinTolmetin may decrease the antihypertensive activities of Bupranolol.Approved
TolonidineBupranolol may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Bupranolol.Approved
TorasemideTorasemide may increase the hypotensive activities of Bupranolol.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Bupranolol.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Bupranolol.Approved
TrazodoneBupranolol may increase the orthostatic hypotensive activities of Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Bupranolol.Approved, Investigational
TribenosideTribenoside may decrease the antihypertensive activities of Bupranolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Bupranolol.Vet Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
TrifluoperazineBupranolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved, Investigational
TriflupromazineTriflupromazine may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
TrimazosinBupranolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Bupranolol.Approved, Investigational
TrimipramineBupranolol may increase the orthostatic hypotensive activities of Trimipramine.Approved
TriptolideTriptolide may decrease the antihypertensive activities of Bupranolol.Investigational
Trolamine salicylateTrolamine salicylate may decrease the antihypertensive activities of Bupranolol.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Bupranolol.Approved
TyrothricinTyrothricin may increase the bradycardic activities of Bupranolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Bupranolol.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Bupranolol.Approved, Investigational
UrapidilBupranolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValaciclovirThe risk or severity of adverse effects can be increased when Bupranolol is combined with Valaciclovir.Approved, Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Bupranolol.Approved, Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Bupranolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Bupranolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Bupranolol can be increased when it is combined with Venlafaxine.Approved
VerapamilVerapamil may increase the hypotensive activities of Bupranolol.Approved
VilanterolBupranolol may decrease the bronchodilatory activities of Vilanterol.Approved
VincamineBupranolol may increase the hypotensive activities of Vincamine.Experimental
XipamideBupranolol may increase the hypotensive activities of Xipamide.Experimental
XylazineXylazine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Vet Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Bupranolol.Approved, Investigational, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Bupranolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Bupranolol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneBupranolol may increase the orthostatic hypotensive activities of Ziprasidone.Approved
ZofenoprilBupranolol may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the antihypertensive activities of Bupranolol.Withdrawn
ZuclopenthixolBupranolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Kunz, W., Jacobi, H., Koch, C. and Geus, R.J.; U.S. Patent 3,309,406; March 14, 1967.

General References
Not Available
External Links
Human Metabolome Database
HMDB0015697
KEGG Drug
D07590
PubChem Compound
2475
PubChem Substance
99445278
ChemSpider
2381
BindingDB
25765
ChEBI
135123
ChEMBL
CHEMBL305380
PharmGKB
PA165958426
IUPHAR
550
Guide to Pharmacology
GtP Drug Page
Wikipedia
Bupranolol
ATC Codes
C07AA19 — Bupranolol

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.143 mg/mLALOGPS
logP3.14ALOGPS
logP2.99ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area41.49 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity74.86 m3·mol-1ChemAxon
Polarizability30.35 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9784
Blood Brain Barrier-0.7572
Caco-2 permeable+0.5576
P-glycoprotein substrateSubstrate0.6384
P-glycoprotein inhibitor INon-inhibitor0.6857
P-glycoprotein inhibitor IINon-inhibitor0.8993
Renal organic cation transporterNon-inhibitor0.8713
CYP450 2C9 substrateNon-substrate0.8011
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6373
CYP450 1A2 substrateInhibitor0.5416
CYP450 2C9 inhibitorNon-inhibitor0.8165
CYP450 2D6 inhibitorInhibitor0.6045
CYP450 2C19 inhibitorNon-inhibitor0.7218
CYP450 3A4 inhibitorNon-inhibitor0.8424
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5726
Ames testNon AMES toxic0.9025
CarcinogenicityNon-carcinogens0.8249
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4441 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9455
hERG inhibition (predictor II)Non-inhibitor0.6443
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Not Available
Direct Parent
Phenol ethers
Alternative Parents
Phenoxy compounds / Toluenes / Chlorobenzenes / Alkyl aryl ethers / Aryl chlorides / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Organochlorides
show 1 more
Substituents
Phenoxy compound / Phenol ether / Alkyl aryl ether / Toluene / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / 1,2-aminoalcohol
show 15 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Zelaszczyk D, Kozlowska H, Baranowska U, Baranowska M, Reutelsterz A, Kiec-Kononowicz K, Malinowska B, Schlicker E: Four close bupranolol analogues are antagonists at the low-affinity state of beta1-adrenoceptors. J Physiol Pharmacol. 2009 Mar;60(1):51-60. [PubMed:19439807]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Lenard NR, Gettys TW, Dunn AJ: Activation of beta2- and beta3-adrenergic receptors increases brain tryptophan. J Pharmacol Exp Ther. 2003 May;305(2):653-9. Epub 2003 Jan 24. [PubMed:12606631]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name
ADRB3
Uniprot ID
P13945
Uniprot Name
Beta-3 adrenergic receptor
Molecular Weight
43518.615 Da
References
  1. Lenard NR, Gettys TW, Dunn AJ: Activation of beta2- and beta3-adrenergic receptors increases brain tryptophan. J Pharmacol Exp Ther. 2003 May;305(2):653-9. Epub 2003 Jan 24. [PubMed:12606631]
  2. Matsushita M, Horinouchi T, Tanaka Y, Tsuru H, Koike K: Characterization of beta 3-adrenoceptor-mediated relaxation in rat abdominal aorta smooth muscle. Eur J Pharmacol. 2003 Dec 15;482(1-3):235-44. [PubMed:14660028]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Iwaki M, Niwa T, Bandoh S, Itoh M, Hirose H, Kawase A, Komura H: Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432. doi: 10.1016/j.dmpk.2016.08.007. Epub 2016 Sep 2. [PubMed:27836712]
  2. Brodde OE, Kroemer HK: Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53(12):814-22. [PubMed:14732961]
  3. Sternieri E, Coccia CP, Pinetti D, Guerzoni S, Ferrari A: Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments. Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):981-1007. doi: 10.1517/17425255.2.6.981 . [PubMed:17125412]

Drug created on October 20, 2010 15:45 / Updated on August 02, 2018 07:45